G-protein-coupled receptors and cancer

G-protein-coupled receptors (GPCRs), the largest family of cell-surface molecules involved in signal transmission, have recently emerged as crucial players in tumour growth and metastasis. Malignant cells often hijack the normal physiological functions of GPCRs to survive, proliferate autonomously, evade the immune system, increase their blood supply, invade their surrounding tissues and disseminate to other organs. This Review will address our current understanding of the many roles of GPCRs and their signalling circuitry in tumour progression and metastasis. We will also discuss how interfering with GPCRs might provide unique opportunities for cancer prevention and treatment.

[1]  P. Insel,et al.  Genetic variation in G-protein-coupled receptors – consequences for G-protein-coupled receptors as drug targets , 2005, Expert opinion on therapeutic targets.

[2]  P. Sánchez,et al.  Gli and hedgehog in cancer: tumours, embryos and stem cells , 2002, Nature Reviews Cancer.

[3]  Y. Niitsu.  A ride on the ferrous wheel , 2004, Cancer biology & therapy.

[4]  T. Hla,et al.  The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia. , 2005, Cancer research.

[5]  B. Barrell,et al.  Human cytomegalovirus encodes three G protein-coupled receptor homologues , 1990, Nature.

[6]  J. Minna,et al.  Autocrine growth factors in human small cell lung cancer. , 1985, Cancer surveys.

[7]  R. Weigel,et al.  Identification of a gene (GPR30) with homology to the G-protein-coupled receptor superfamily associated with estrogen receptor expression in breast cancer. , 1997, Genomics.

[8]  R. Leurs,et al.  HCMV-encoded G-protein-coupled receptors as constitutively active modulators of cellular signaling networks. , 2006, Trends in pharmacological sciences.

[9]  J. Nelson,et al.  Identification of endothelin–1 in the pathophysiology of metastatic adenocarcinoma of the prostate , 1995, Nature Medicine.

[10]  I. Macdonald,et al.  Metastasis: Dissemination and growth of cancer cells in metastatic sites , 2002, Nature Reviews Cancer.

[11]  J. Shah,et al.  Cyclooxygenase‐2: A novel molecular target for the prevention and treatment of head and neck cancer , 2002, Head & neck.

[12]  M. Brann,et al.  Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[13]  R. Lefkowitz,et al.  Activity-Dependent Internalization of Smoothened Mediated by ß-Arrestin 2 and GRK2 , 2004, Science.

[14]  J. Kehrl,et al.  The G12 family of heterotrimeric G proteins and Rho GTPase mediate Sonic hedgehog signalling , 2004, Genes to cells : devoted to molecular & cellular mechanisms.

[15]  Sergio Romagnani,et al.  An Alternatively Spliced Variant of CXCR3 Mediates the Inhibition of Endothelial Cell Growth Induced by IP-10, Mig, and I-TAC, and Acts as Functional Receptor for Platelet Factor 4 , 2003, The Journal of experimental medicine.

[16]  H. Moch,et al.  Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL , 2003, Nature.

[17]  J. Madden,et al.  Bradykinin receptor subtype 1 expression and function in prostate cancer. , 2003, Cancer research.

[18]  J. Gutkind,et al.  G-protein-coupled receptors and signaling networks: emerging paradigms. , 2001, Trends in pharmacological sciences.

[19]  Reuven Reich,et al.  Thrombin receptor overexpression in malignant and physiological invasion processes , 1998, Nature Medicine.

[20]  T. Mak,et al.  Polarization of Chemoattractant Receptor Signaling During Neutrophil Chemotaxis , 2022 .

[21]  P. Steeg.  Metastasis suppressors alter the signal transduction of cancer cells , 2003, Nature Reviews Cancer.

[22]  Z. Werb,et al.  How matrix metalloproteinases regulate cell behavior. , 2001, Annual review of cell and developmental biology.

[23]  D. Doyle,et al.  Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor. , 1999, The New England journal of medicine.

[24]  J. Dong,et al.  Identity of an estrogen membrane receptor coupled to a G protein in human breast cancer cells. , 2005, Endocrinology.

[25]  Lawrence Lum,et al.  The Hedgehog Response Network: Sensors, Switches, and Routers , 2004, Science.

[26]  D J Mooney,et al.  Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. , 2001, Cancer research.

[27]  K. Bland,et al.  Estrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF. , 2000, Molecular endocrinology.

[28]  R. DuBois,et al.  Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[29]  J. Rees.  Genetics of hair and skin color. , 2003, Annual review of genetics.

[30]  N. Riobo,et al.  Activation of heterotrimeric G proteins by Smoothened , 2006, Proceedings of the National Academy of Sciences.

[31]  Donald P. McDonnell,et al.  Connections and Regulation of the Human Estrogen Receptor , 2002, Science.

[32]  E. Cesarman,et al.  Human herpesvirus KSHV encodes a constitutively active G-protein-coupled receptor linked to cell proliferation , 1997, Nature.

[33]  A. Grossman,et al.  Malignant Pituitary Tumours , 1998, Pituitary.

[34]  Prahlad T. Ram,et al.  G Protein Pathways , 2002, Science.

[35]  A. Schally,et al.  Inhibition of Growth of Experimental Human and Hamster Pancreatic Cancers In Vivo by a Targeted Cytotoxic Bombesin Analog , 2005, Pancreas.

[36]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[37]  S. Milstien,et al.  Targeting sphingosine-1-phosphate: a novel avenue for cancer therapeutics. , 2006, Cancer cell.

[38]  G. Mills,et al.  Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer. , 2006, Cancer research.

[39]  J. Rubin,et al.  Rapid, Wnt-Induced Changes in GSK3β Associations that Regulate β-Catenin Stabilization Are Mediated by Gα Proteins , 2005, Current Biology.

[40]  Q. Gu,et al.  Activating Smoothened mutations in sporadic basal-cell carcinoma , 1998, Nature.

[41]  Akira Kikuchi,et al.  Tumor formation by genetic mutations in the components of the Wnt signaling pathway , 2003, Cancer science.

[42]  K. Nakayama,et al.  Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination. , 2005, Molecular and cellular biology.

[43]  G. Hortobagyi,et al.  Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis. , 2004, Cancer cell.

[44]  A. Agarwal,et al.  PAR1 Is a Matrix Metalloprotease-1 Receptor that Promotes Invasion and Tumorigenesis of Breast Cancer Cells , 2005, Cell.

[45]  L. Gesualdo,et al.  Sirolimus for Kaposi's sarcoma in renal-transplant recipients. , 2005, The New England journal of medicine.

[46]  E. A. van Rijthoven,et al.  Expression of pertussis toxin adenosine diphosphate-ribosyltransferase in a T-cell hybridoma reduces metastatic capacity. , 1996, Blood.

[47]  W. Zhang,et al.  PSGR, a novel prostate-specific gene with homology to a G protein-coupled receptor, is overexpressed in prostate cancer. , 2000, Cancer research.

[48]  K. Nakayama,et al.  Phosphorylation of β-Catenin by Cyclic AMP-Dependent Protein Kinase Stabilizes β-Catenin through Inhibition of Its Ubiquitination , 2005, Molecular and Cellular Biology.

[49]  K. Kinzler,et al.  PPAR d Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999 .

[50]  Y. Daaka.  G Proteins in Cancer: The Prostate Cancer Paradigm , 2004, Science's STKE.

[51]  K. Kinzler,et al.  Cancer genes and the pathways they control , 2004, Nature Medicine.

[52]  M. Hull,et al.  Prostaglandin EP receptors: targets for treatment and prevention of colorectal cancer? , 2004, Molecular cancer therapeutics.

[53]  C. Malbon,et al.  Frizzleds: new members of the superfamily of G-protein-coupled receptors. , 2004, Frontiers in bioscience : a journal and virtual library.

[54]  P. Casey,et al.  Androgen Receptor Activation by Gs Signaling in Prostate Cancer Cells* , 2005, Journal of Biological Chemistry.

[55]  G. Mills,et al.  Lysophosphatidic Acid Is a Major Regulator of Growth-Regulated Oncogene α in Ovarian Cancer , 2006 .

[56]  Rob Leurs,et al.  Constitutive Signaling of the Human Cytomegalovirus-encoded Chemokine Receptor US28* , 2001, The Journal of Biological Chemistry.

[57]  Olgatina Bucco,et al.  G-Protein-Coupled Receptors in Drug Discovery: Nanosizing Using Cell-Free Technologies and Molecular Biology Approaches , 2005, Journal of biomolecular screening.

[58]  H. Sheng,et al.  Prostaglandin E2 Stimulates the β-Catenin/T Cell Factor-dependent Transcription in Colon Cancer* , 2005, Journal of Biological Chemistry.

[59]  Y. Hirooka,et al.  Interleukin-8 Promoter Polymorphism Increases the Risk of Atrophic Gastritis and Gastric Cancer in Japan , 2005, Cancer Epidemiology Biomarkers & Prevention.

[60]  C. Cobbs,et al.  Human cytomegalovirus infection and expression in human malignant glioma. , 2002, Cancer research.

[61]  S. Costagliola,et al.  Activating mutations of TSH receptor. , 2004, Annales d'endocrinologie.

[62]  L. Chin.  The genetics of malignant melanoma: lessons from mouse and man , 2003, Nature Reviews Cancer.

[63]  Rob Leurs,et al.  Human cytomegalovirus-encoded chemokine receptor US28 promotes tumorigenesis , 2006, Proceedings of the National Academy of Sciences.

[64]  R. DuBois,et al.  COX-2: a molecular target for colorectal cancer prevention. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  M. Burdick,et al.  Cancer CXC chemokine networks and tumour angiogenesis. , 2006, European journal of cancer.

[66]  Y. Kubota,et al.  Renin‐angiotensin system is an important factor in hormone refractory prostate cancer , 2006, The Prostate.

[67]  Ajamete Kaykas,et al.  WNT and β-catenin signalling: diseases and therapies , 2004, Nature Reviews Genetics.

[68]  J. Redondo,et al.  Cyclooxygenase-2: a therapeutic target in angiogenesis. , 2003, Trends in molecular medicine.

[69]  E. Rozengurt,et al.  Gastrointestinal peptide signalling in health and disease. , 2002, The European journal of surgery. Supplement. : = Acta chirurgica. Supplement.

[70]  M. Burdick,et al.  Cyclooxygenase-2-Dependent Expression of Angiogenic CXC Chemokines ENA-78/CXC Ligand (CXCL) 5 and Interleukin-8/CXCL8 in Human Non-Small Cell Lung Cancer , 2004, Cancer Research.

[71]  Hani Doss,et al.  Aspirin, ibuprofen, and other non-steroidal anti-inflammatory drugs in cancer prevention: a critical review of non-selective COX-2 blockade (review). , 2005, Oncology reports.

[72]  M. Wigler,et al.  Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains , 1986, Cell.

[73]  S. Narumiya,et al.  Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice , 2001, Nature Medicine.

[74]  Robert Riddell,et al.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. , 2005, The New England journal of medicine.

[75]  C. Lebbé,et al.  Association between endothelin receptor B nonsynonymous variants and melanoma risk. , 2005, Journal of the National Cancer Institute.

[76]  K. Druey,et al.  Prostaglandin E2 Promotes Colon Cancer Cell Growth Through a Gs-Axin-ß-Catenin Signaling Axis , 2005, Science.

[77]  M. Rosenkilde.  Virus-encoded chemokine receptors – putative novel antiviral drug targets , 2005, Neuropharmacology.

[78]  K. Kinzler,et al.  PPARδ Is an APC-Regulated Target of Nonsteroidal Anti-Inflammatory Drugs , 1999, Cell.

[79]  E. Ariazi,et al.  Estrogen receptors as therapeutic targets in breast cancer. , 2006, Current topics in medicinal chemistry.

[80]  R. Salcedo,et al.  Role of Chemokines in Angiogenesis: CXCL12/SDF‐1 and CXCR4 Interaction, a Key Regulator of Endothelial Cell Responses , 2003, Microcirculation.

[81]  J M Trent,et al.  KiSS-1, a novel human malignant melanoma metastasis-suppressor gene. , 1996, Journal of the National Cancer Institute.

[82]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[83]  T. Moody,et al.  [Psi 13,14] bombesin analogues inhibit growth of small cell lung cancerin vitro and in vivo. , 1991, Cancer research.

[84]  Hiroyuki Aburatani,et al.  Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis , 2006, Nature Cell Biology.

[85]  M. Zemel,et al.  Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. , 2002, Cancer research.

[86]  R. Lefkowitz,et al.  Signalling: Seven-transmembrane receptors , 2002, Nature Reviews Molecular Cell Biology.

[87]  T. Hla.  Signaling and biological actions of sphingosine 1-phosphate. , 2003, Pharmacological research.

[88]  D. Dockrell.  Human herpesvirus 6: molecular biology and clinical features. , 2003, Journal of medical microbiology.

[89]  E. Kawasaki,et al.  Two G protein oncogenes in human endocrine tumors. , 1990, Science.

[90]  N. Tsopanoglou,et al.  Role of thrombin in angiogenesis and tumor progression. , 2004, Seminars in thrombosis and hemostasis.

[91]  C. Der,et al.  Persistent Signaling by Dysregulated Thrombin Receptor Trafficking Promotes Breast Carcinoma Cell Invasion , 2004, Molecular and Cellular Biology.

[92]  L. Bardwell,et al.  Constitutive overexpression of a growth-regulated gene in transformed Chinese hamster and human cells. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[93]  O. Nishimura,et al.  Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor , 2001, Nature.

[94]  J. Gutkind,et al.  Cell growth control by G protein-coupled receptors: from signal transduction to signal integration , 1998, Oncogene.

[95]  Ravi Salgia,et al.  Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells. , 2002, Cancer research.

[96]  A. Sica,et al.  Epidermal Growth Factor and Hypoxia-induced Expression of CXC Chemokine Receptor 4 on Non-small Cell Lung Cancer Cells Is Regulated by the Phosphatidylinositol 3-Kinase/PTEN/AKT/Mammalian Target of Rapamycin Signaling Pathway and Activation of Hypoxia Inducible Factor-1α* , 2005, Journal of Biological Chemistry.

[97]  L. Brass,et al.  Protease-activated receptors (PAR1 and PAR2) contribute to tumor cell motility and metastasis. , 2004, Molecular cancer research : MCR.

[98]  R. Epstein.  The CXCL12–CXCR4 chemotactic pathway as a target of adjuvant breast cancer therapies , 2004, Nature Reviews Cancer.

[99]  Geoffrey C Gurtner,et al.  Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1 , 2004, Nature Medicine.

[100]  T. Mcclanahan,et al.  Involvement of chemokine receptors in breast cancer metastasis , 2001, Nature.

[101]  D. Duffy,et al.  Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? , 2000, American journal of human genetics.

[102]  V. Holla,et al.  Prostaglandin E2 Regulates the Nuclear Receptor NR4A2 in Colorectal Cancer* , 2006, Journal of Biological Chemistry.

[103]  L. Heasley,et al.  Autocrine and paracrine signaling through neuropeptide receptors in human cancer , 2001, Oncogene.

[104]  A. Tarnawski,et al.  PGE(2) stimulates VEGF expression in endothelial cells via ERK2/JNK1 signaling pathways. , 2001, Biochemical and biophysical research communications.

[105]  C. Van Waes,et al.  Constitutive activation of transcription factors NF‐κB, AP‐1, and NF‐IL6 in human head and neck squamous cell carcinoma cell lines that express pro‐inflammatory and pro‐angiogenic cytokines , 1999, Molecular carcinogenesis.

[106]  Eric R. Prossnitz,et al.  A Transmembrane Intracellular Estrogen Receptor Mediates Rapid Cell Signaling , 2005, Science.

[107]  M. Laburthe,et al.  Aberrant expression and activation of the thrombin receptor protease-activated receptor-1 induces cell proliferation and motility in human colon cancer cells. , 2003, The American journal of pathology.

[108]  H. Welch,et al.  PI3K and RAC signalling in leukocyte and cancer cell migration. , 2006, Bulletin du cancer.

[109]  J. Pouysségur,et al.  Angiogenesis and G-protein-coupled receptors: signals that bridge the gap , 2001, Oncogene.

[110]  G. Anderson,et al.  Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. , 2003, Cancer research.

[111]  R. Nusse,et al.  Wnt signaling in disease and in development , 2005, Cell Research.

[112]  N. Fujii,et al.  Kisspeptin-10-induced signaling of GPR54 negatively regulates chemotactic responses mediated by CXCR4: a potential mechanism for the metastasis suppressor activity of kisspeptins. , 2005, Cancer research.

[113]  G. Clayman,et al.  Expression of protease-activated receptor 1 in oral squamous cell carcinoma. , 2001, Cancer letters.

[114]  T. Jessell,et al.  Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. , 1989, Science.

[115]  M. Vadas,et al.  Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling , 2005, The Journal of experimental medicine.

[116]  G. Mills,et al.  The emerging role of lysophosphatidic acid in cancer , 2003, Nature Reviews Cancer.

[117]  A. Tarnawski,et al.  Prostaglandin E2 transactivates EGF receptor: A novel mechanism for promoting colon cancer growth and gastrointestinal hypertrophy , 2002, Nature Medicine.

[118]  T. Moody,et al.  [Psi13,14] Bombesin Analogues Inhibit Growth of Small Cell Lung Cancer in Vitro and in Vivo , 1991 .

[119]  J. Gutkind,et al.  Viral hijacking of G-protein-coupled-receptor signalling networks , 2004, Nature Reviews Molecular Cell Biology.

[120]  T. Hoffman,et al.  Radiolabeled peptide conjugates for targeting of the bombesin receptor superfamily subtypes. , 2005, Nuclear medicine and biology.

[121]  E. Sausville,et al.  The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor. , 2006, Cancer cell.

[122]  R. Moon,et al.  Activation of Rat Frizzled-1 Promotes Wnt Signaling and Differentiation of Mouse F9 Teratocarcinoma Cells via Pathways That Require Gαq and Gαo Function* , 1999, The Journal of Biological Chemistry.

[123]  L. Heasley,et al.  G protein-coupled receptor systems involved in cell growth and oncogenesis. , 1995, Endocrine reviews.

[124]  G. Semenza,et al.  Stromal Cell–Derived Factor-1α and CXCR4 Expression in Hemangioblastoma and Clear Cell-Renal Cell Carcinoma: von Hippel-Lindau Loss-of-Function Induces Expression of a Ligand and Its Receptor , 2005 .

[125]  Hiromu Suzuki,et al.  Mammary gland tissue targeted overexpression of human protease-activated receptor 1 reveals a novel link to beta-catenin stabilization. , 2006, Cancer research.

[126]  H. Bourne,et al.  GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours , 1989, Nature.

[127]  M. Zemel,et al.  Prostaglandin E2 Protects Intestinal Tumors from Nonsteroidal Anti-inflammatory Drug-induced Regression in ApcMin/+ Mice , 2002 .

[128]  Yi-ping Lin,et al.  The −251T Allele of the Interleukin-8 Promoter Is Associated with Increased Risk of Gastric Carcinoma Featuring Diffuse-Type Histopathology in Chinese Population , 2005, Clinical Cancer Research.

[129]  A. Schally,et al.  Targeting cytotoxic conjugates of somatostatin, luteinizing hormone-releasing hormone and bombesin to cancers expressing their receptors: a "smarter" chemotherapy. , 2005, Current pharmaceutical design.

[130]  F. Wamunyokoli,et al.  A growth-related oncogene/CXC chemokine receptor 2 autocrine loop contributes to cellular proliferation in esophageal cancer. , 2006, Cancer research.

[131]  B. Rollins,et al.  Inflammatory chemokines in cancer growth and progression. , 2006, European journal of cancer.

[132]  M. Burdick,et al.  Depletion of CXCR2 Inhibits Tumor Growth and Angiogenesis in a Murine Model of Lung Cancer1 , 2004, The Journal of Immunology.

[133]  H. Yoshida,et al.  The clinicopathological significance of the expression of CXCR4 protein in oral squamous cell carcinoma. , 2004, International journal of oncology.

[134]  N. Hayward.  Genetics of melanoma predisposition , 2003, Oncogene.

[135]  G. Giannattasio,et al.  Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas , 1987, Nature.

[136]  Hui Xiong,et al.  beta-Catenin activates the growth factor endothelin-1 in colon cancer cells. , 2005, Oncogene.

[137]  H. Plummer,et al.  The tobacco-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone is a beta-adrenergic agonist and stimulates DNA synthesis in lung adenocarcinoma via beta-adrenergic receptor-mediated release of arachidonic acid. , 1999, Cancer research.

[138]  Rajnish A. Gupta,et al.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2 , 2001, Nature Reviews Cancer.

[139]  S. Ferrari,et al.  A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer , 2003, The EMBO journal.

[140]  J. Rubin,et al.  Rapid, Wnt-induced changes in GSK3beta associations that regulate beta-catenin stabilization are mediated by Galpha proteins. , 2005, Current biology : CB.

[141]  M. Caron,et al.  G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[142]  S. Coughlin,et al.  Thrombin signalling and protease-activated receptors , 2000, Nature.

[143]  J. Waxman,et al.  COX inhibitors and breast cancer , 2006, British Journal of Cancer.

[144]  D. Schadendorf,et al.  Association between endothelin receptor B nonsynonymous variants and melanoma risk. , 2006 .

[145]  T. Hla,et al.  Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice* , 2001, The Journal of Biological Chemistry.

[146]  Yiling Lu,et al.  Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. , 2006, Cancer cell.

[147]  J. Behrens,et al.  The Wnt connection to tumorigenesis. , 2004, The International journal of developmental biology.

[148]  Jürgen Schymeinsky,et al.  Human neutrophils promote angiogenesis by a paracrine feedforward mechanism involving endothelial interleukin-8. , 2005, American journal of physiology. Heart and circulatory physiology.

[149]  E. Ariazi,et al.  Estrogen-related receptors as emerging targets in cancer and metabolic disorders. , 2006, Current topics in medicinal chemistry.

[150]  C. Malbon.  β-Catenin, Cancer, and G Proteins: Not Just for Frizzleds Anymore , 2005, Science's STKE.

[151]  M. Rosenkilde,et al.  Epstein-Barr Virus-Encoded BILF1 Is a Constitutively Active G Protein-Coupled Receptor , 2005, Journal of Virology.

[152]  T. Kipps,et al.  CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. , 2006, Blood.

[153]  Y. Yatabe,et al.  Increased expression of cyclooxygenase 2 occurs frequently in human lung cancers, specifically in adenocarcinomas. , 1998, Cancer research.

[154]  G. Semenza.  Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.

[155]  J. Siegfried,et al.  Gastrin-releasing peptide receptor-mediated autocrine growth in squamous cell carcinoma of the head and neck. , 2002, Journal of the National Cancer Institute.

[156]  J. Parma,et al.  Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas , 1993, Nature.

[157]  H. Fritsche,et al.  Calcium-induced activation of a mutant G-protein-coupled receptor causes in vitro transformation of NIH/3T3 cells. , 1999, Neoplasia.

[158]  G. Johnson,et al.  Gα12 and Gα13 Stimulate Rho-dependent Stress Fiber Formation and Focal Adhesion Assembly (*) , 1995, The Journal of Biological Chemistry.

[159]  R. Schüle,et al.  FHL2, a novel tissue‐specific coactivator of the androgen receptor , 2000, The EMBO journal.

[160]  S. Patierno,et al.  Tissue factor and fibrin in tumor angiogenesis. , 2004, Seminars in thrombosis and hemostasis.

[161]  R. Jain,et al.  The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis , 2004, Nature.